SCIENTIFIC EXCELLENCE

CONTEXT 

Scientific research on gene and cellular therapies increased substantially over the last years. With Real World Data becoming increasingly available, many scientific questions, from different perspectives, can be explored. Only by working together can we leverage enough data to conduct meaningful research. GoCART wants to maximise the use of data collected in the central EBMT registry as well as data available to other stakeholders, and to facilitate further collaboration between stakeholders. While strongly protecting confidentiality, the guiding principle should be ‘collect once, use often’ to advance our knowledge in the field of gene and cellular therapies, support better decision making and drive efficiencies for all stakeholders.

 

OVERALL AIM

Stimulate scientific discussion across stakeholders, facilitate the set-up of joint research projects and avoid duplication of scientific efforts.

CURRENT ACTIVITIES

Yearly calls for research proposals to promote the conduct of collaborative studies.

 

MAIN ACHIEVEMENTS TO DATE

GoCART has released three calls for proposals, one in each of 2021, 2022 and 2023.

The studies are conducted by a dedicated GoCART Study Team based at EBMT consisting of a study coordinator, data manager and statisticians.

GoCART is supporting the following winning proposals:

  1. Comparison of allogeneic hematopoietic stem cell transplantation with chimeric antigen receptor T-cells in relapsed and refractory large B cell lymphoma
    Lead PI: Bertram Glass (Germany)
  2. Patterns of relapse after commercial use of anti-CD19 CART therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
    Lead PI: Alberto Mussetti (Italy)
  3. Impact of preceding therapy of CART Cells in B-ALL and impact of consolidative HCT following complete remission post CART
    Lead PI: Valentin Ortíz-Maldonado (Spain)
  4. Autoimmune and auto inflammatory complications after CAR-T cell therapy
    Lead PI: Matteo Doglio (Italy)
  5. Efficacy and toxicity of CAR-T cell therapy in patients with primary and secondary central nervous system lymphoma
    Lead PI: Anna Laube (Germany)
  6. Infections following CAR-T cell therapy
    Lead PI: Dina Averbuch (Israel)
  7. The role of bridging therapy before CAR-T cell therapy in diffuse large B-cell lymphoma
    Lead PI: Philipp Berning (Germany)
  8. Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR-T cell therapy in aggressive B-cell malignancies
    Lead PI: Jan C. Schröder (Germany)

The next call for proposals will come out in June 2024.